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Abstract  1 
The herb Cannabis sativa (C. sativa) has been used in China and on the Indian 2 
subcontinent for thousands of years as a medicine. However, since it was brought to the 3 
U.K. and then the rest of the western world in the late 19
th
 century, its use has been a 4 
source of controversy. Indeed, its psychotropic side effects are well reported but only 5 
relatively recently has scientific endeavour begun to find valuable uses for either the 6 
whole plant or its individual components. Here, we discuss evidence describing the 7 
endocannabinoid system, its endogenous and exogenous ligands and their varied effects 8 
on feeding cycles and meal patterns. Furthermore we also critically consider the 9 
mounting evidence which suggests non-∆9tetrahydrocannabinol phytocannabinoids play 10 
a vital role in C. sativa-induced feeding pattern changes. Indeed, given the wide range 11 
of phytocannabinoids present in C. sativa and their equally wide range of intra-, inter- 12 
and extra-cellular mechanisms of action, we demonstrate that non-13 
∆9tetrahydrocannabinol phytocannabinoids retain an important and, as yet,  untapped 14 
clinical potential. 15 
 16 
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Introduction  1 
For ~10,000 years, Cannabis sativa (C. sativa) has been used medicinally and 2 
recreationally for its diverse pharmacological actions and psychotropic properties. 3 
Typical actions include sedation, analgesia, hypothermia, catalepsy and euphoria which 4 
are thought to arise mainly from cannabinoid type 1 receptor (CB1R) activation 5 
(Childers et al., 1998; Little et al., 1988). These effects have typically been ascribed to 6 
the sixty (Howlett, 2002; Pertwee, 2008b) to eighty (Izzo et al., 2009) 7 
phytocannabinoids (pCBs) present in C. sativa. In more recent times, C. sativa has been 8 
used less widely for medicinal purposes, due in part to the development of other 9 
therapeutic agents with better side effect profiles (e.g. Tramer et al., 2001). Indeed, 10 
cannabinoid side-effects are known to include reduced motor coordination, tachycardia, 11 
transient memory loss, disruption to the sense of time, cognitive impairments, anxiety 12 
and a disruption of appetite regulation (Childers et al., 1998; Dewey, 1986; Grant et al., 13 
2005; Hollister, 1986; Kirkham et al., 2001b; Wilkinson et al., 2003) (for a recent 14 
review on the safety of C. sativa-based therapy see Wang et al., 2008). However, the 15 
relatively recent identification of the CB1R and cannabinoid type 2 (CB2R) receptors, 16 
alongside the subsequent characterisation of the endocannabinoid (eCB) system (for a 17 
recent review see Maccarrone, 2009), has driven a resurgence of interest in the potential 18 
applications of cannabinoid-based therapy. Cannabinoid therapies have now been 19 
investigated for a wide range of neurological and neurodegenerative disorders (Glass, 20 
2001; Pryce et al., 2003), both in terms of treatment (for a review see Consroe, 1998) 21 
and/or symptom management (Davis et al., 2007). One notable example is in the 22 
treatment of multiple sclerosis (Pryce et al., 2005) and its symptoms (eg. spasticity), for 23 
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which a cannabis-based compound (Sativex®) has recently been licensed in the U.K., 1 
Spain and Canada by GW Pharmaceuticals.  2 
 ‘Cannabinoid’ is a well-known term used to describe the compounds isolated 3 
from C. Sativa, the pCBs such as ∆9tetrahydrocannabinol (∆9THC), cannabidiol (CBD) 4 
and cannabinol (CBN). In addition to these, the term now also encompasses both 5 
synthetic exogenous (e.g. SR141716A, a CB1R specific antagonist/inverse agonist) and 6 
endogenously produced ligands (the eCBs anandamide (AEA) and 2-arachidonyl 7 
glycerol (2-AG)) at CB1- and CB2Rs (for an overview of the cannabinoid receptor 8 
(CBR) ligands referred to in this review, see table 1). The development and 9 
characterisation of such pharmacological tools has enabled significant progress to be 10 
made into understanding the eCB system over the last 20 years (Onaivi et al., 2002). 11 
∆9THC, the main psychoactive component in C. sativa, was first isolated and 12 
synthesised in 1964 by Gaoni et al. (Gaoni et al., 1964a). However, it was not until 13 
1988 that the first cannabinoid specific G-protein coupled receptor (GPCR; CB1R) at 14 
which it acts was characterised (Devane et al., 1988; Matsuda et al., 1990), lending 15 
credence to the postulated existence of an eCB system (Howlett et al., 1990) (for review 16 
see Pertwee, 2005). A series of studies (Herkenham et al., 1991; Herkenham et al., 17 
1990) identifying the widespread expression of this receptor in the brain further 18 
supported this discovery. These findings were rapidly followed by the isolation and 19 
structural determination of the first eCB ligand, AEA, in 1992 (Devane et al., 1992), the 20 
identification and characterisation of CB2R expressed on immune cells, in 1993 (Munro 21 
et al., 1993), and the identification of a second eCB ligand, 2-AG, in 1995 (Mechoulam 22 
et al., 1995b; Sugiura et al., 1995) (See Fig.1). Since then, significant academic and 23 
commercial effort has been invested in characterising and exploiting the eCB system 24 
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(for example reviews see Basavarajappa, 2007a; Basavarajappa, 2007b; Bisogno et al., 1 
2005; Freund et al., 2003). 2 
As previously outlined, it is now apparent that the eCB system is physiologically 3 
ubiquitous and linked to many pathophysiological states (de Fonseca, 2005), resulting in 4 
its identification as a therapeutic target, as well as the publication of numerous reviews 5 
regarding the potential benefits of cannabinoid based therapies (e.g. Agrawal et al., 6 
2009; Baker et al., 2003; Glass, 2001; Goutopoulos et al., 2002; Makriyannis et al., 7 
2005). This is particularly true in the field of body weight regulation and energy balance 8 
(Yates et al., 2009), where significant advances have been made in the development of 9 
both anti-anorectic (e.g. in hepatitis C (Costiniuk et al., 2008); in cancer (Walsh et al., 10 
2003); in human immunodeficiency virus (HIV) (Woolridge et al., 2005)) and anti-11 
obesity (Van Gaal et al., 2005) cannabinoid-based therapies. However, these advances 12 
must be made with care (Grant et al., 2005), and it is clear that further long-term studies 13 
are warranted if the safety profiles of such therapies are to be fully understood (Wang et 14 
al., 2008). Indeed, the withdrawal of Acomplia (Rimonabant: SR141716A; see EMA, 15 
2009 for details) from clinical use for the treatment of obesity due to serious cognitive 16 
side effects, combined with the cessation of Phase III clinical trials for a second putative 17 
anti-obesity drug, Taranabant (MK-0364; Clark, 2009), illustrates the difficulties of 18 
manipulating such a complex and ubiquitous system. Nonetheless, it is clear that the 19 
eCB system plays an important, if not yet fully understood, role in appetite, obesity and 20 
energy balance (for reviews see Cota et al., 2003a; Kirkham, 2008). This review will 21 
describe the significant progress made, as well as the work still required, in order to 22 
fully understand the role played by the eCB system in feeding and appetite regulation. 23 
Importantly, by focusing on those studies that have examined pCB effects and how they 24 
6 
 
 
might interact with the eCB system to modulate appetite and feeding, this review 1 
provides insight into the potential use of these compounds as therapeutic tools in the 2 
treatment of eating- and weight-related disorders.  3 
 4 
 5 
6 
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The endocannabinoid system in the central nervous system 1 
Although, CBRs are present in both the peripheral and central nervous systems (CNS), 2 
the majority of cannabinoid feeding research to date has focused primarily on centrally-3 
mediated feeding mechanisms, a focus that is consequently reflected in this review. A 4 
short section outlining the biological components that comprise the eCB system within 5 
the CNS is presented hereafter (see also figures 2 and 3). 6 
ECBs (AEA and 2-AG) are produced on demand by postsynaptic neurons (Di 7 
Marzo et al., 2004) in the CNS in response to rises in intracellular [Ca
2+
] (Cadas et al., 8 
1997; Di Marzo et al., 1994). Such increases typically occur following Gq-coupled 9 
receptor activation which stimulates production of inositol trisphosphate (IP3) by 10 
phospholipase C (PLC) leading to a release of Ca
2+
 from intracellular stores (for 11 
reviews see Berridge, 1995; Berridge et al., 1988; Putney Jr, 1986). Alternatively, 12 
ionotropic glutamate receptor activation permits the influx of Ca
2+
 to increase eCB 13 
production (Freund et al., 2003).  14 
AEA synthesis from its precursors, arachidonic acid and N-arachidonoyl 15 
phosphatidyl-ethanolamine (NaPE) is an on demand effect. Phosphatidylethanolamine is 16 
first catalysed by Ca
2+
-dependent N-acyltransferase (Cadas et al., 1997) into NaPE 17 
(although Ca
2+
-independent processes have also been proposed; Jin et al., 2007); NaPE 18 
is then converted to the N-acylethanolamine,  AEA, (Di Marzo et al., 1994) by NaPE 19 
phospholipase-D (Okamoto et al., 2004). However, it has been suggested that at least 20 
three other pathways for AEA synthesis may also exist (for reviews, see Liu et al., 21 
2008; Okamoto et al., 2009a; Okamoto et al., 2009b). 2-AG is formed by the 22 
diacylglycerol (DAG) lipases α and β-catalyzed hydrolysis of DAG (Di Marzo et al., 23 
2007). After formation, eCB release into the extracellular space is thought to occur 24 
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immediately via passive diffusion or through a putative eCB transporter as no storage 1 
systems for eCBs have yet been identified and some eCB precursors are known to be 2 
membrane bound, suggesting that eCBs are produced at their release site (Di Marzo, 3 
2008; Pope et al, 2010.). 4 
Once released into the intercellular space, unlike classical neurotransmission, 5 
eCB signalling is retrograde such that eCBs released from a postsynaptic neuron diffuse 6 
across the synaptic cleft to bind with presynaptically located CB1Rs to exert effects (see 7 
figure 3; Ohno-Shosaku et al., 2001; Piomelli et al., 2000; Wilson et al., 2001) that are 8 
now thought to be intimately linked to synaptic plasticity (see Alger, 2009). The 9 
activation of presynaptic CB1Rs by AEA and 2-AG induces a PLC-β-mediated 10 
suppression of [Ca
2+
] entry and a protein kinase A (PKA)-mediated upregulation of [K
+
] 11 
efflux, thereby driving neuronal resting membrane potential to more hyperpolarized 12 
values and so reducing the further pre-synaptic release of neurotransmitter (for review 13 
see Mackie, 2006; Südhof et al., 2008). Indeed, presynaptically it has been conclusively 14 
demonstrated that CB1R activation has a direct effect on membrane polarisation, for 15 
example, in cultured hippocampal neurones (Deadwyler et al., 1995; Schweitzer, 2000) 16 
and in CA1 pyramidal cells (Kirby et al., 2000).  17 
ECB reuptake however remains the subject of much debate. Fatty acid amide 18 
hydrolase (FAAH; Cravatt et al., 1996) and monoacylglycerol lipase (MAGL; Lambert 19 
et al., 2005) are the two main enzymes involved in eCB degradation, and have been 20 
known to degrade AEA and 2-AG for some time. However, although a specific 21 
transmembrane  transporter protein has yet to be identified, it seems that reuptake may 22 
be a rapid carrier-mediated transport process (e.g. Gerdeman et al., 2002; Ronesi et al., 23 
2004) since eCBs within the synaptic cleft are almost immediately inactivated (Di 24 
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Marzo et al., 2007). 2-AG is typically inactivated by MAGL (Di Marzo, 2008) but also 1 
to some extent by FAAH (Blankman et al., 2007), whereas, AEA is thought to be 2 
degraded by FAAH alone (Vandevoorde, 2008). Four mechanisms are currently 3 
proposed to underlie eCB reuptake; a membrane-localised transmembrane carrier 4 
protein, FAAH-induced passive diffusion through the lipid bilayer, the creation of 5 
caveolae with AEA binding sites on the cell membrane which then internalise AEA 6 
and/or 2-AG, and via intracellular sequestration into the cell within a lipid shell (for a 7 
recent review see Yates et al., 2009). Intracellular FAAH-mediated AEA hydrolysis 8 
creates arachidonic acid and ethanolamine (Deutsch et al., 2002 thoroughly review the 9 
biochemistry of FAAH) whilst 2-AG undergoes primarily MAGL-mediated hydrolysis 10 
into arachidonic acid and glycerol (Blankman et al., 2007).  11 
While the mechanisms involved in AEA and 2-AG degradation remain poorly 12 
understood, it is clear that FAAH and MAGL blockade could be of therapeutic value. 13 
FAAH inhibition, for instance by URB597 (Piomelli et al., 2006; see Vandevoorde, 14 
2008 for a review of FAAH and MAGL inhibitors), is expected to potentiate AEA 15 
effects (and to some extent 2-AG). Such inhibition could, for instance, be expected to 16 
have effects on energy homeostasis as AEA and 2-AG administration into the 17 
hypothalamic nuclei has been conclusively demonstrated to induce hyperphagia in rats 18 
(Jamshidi et al., 2001; Kirkham et al., 2001a; Kirkham et al., 2002). Consequently, 19 
increasing AEA concentrations in the synaptic cleft via FAAH inhibition could produce 20 
similar effects. Although MAGL inhibition (e.g. by URB602; King et al., 2007) which 21 
could potentiate 2-AG effects is less well studied than FAAH inhibition, it too could be 22 
of comparable therapeutic use. It is however important to consider that both FAAH and 23 
MAGL inhibition could have secondary effects besides increasing AEA and 2-AG 24 
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levels respectively. For instance, some evidence suggests that FAAH inhibition can also 1 
decrease 2-AG levels (see Di Marzo et al., 2008 for a review of these data), and MAGL 2 
inhibition, by the particularly potent and selective MAGL inhibitor JZL-184, has been 3 
found to induce behavioural effects similar to those produced by agonist-induced CB1R 4 
activation (Long et al., 2009). The dynamic interplay between these systems must be 5 
taken into account when considering new therapeutic approaches if unwanted side-6 
effects are to be minimised. 7 
The cannabinoid receptors, CB1 and CB2R, are members of the superfamily of 8 
GPCRs and are characterised by seven transmembrane helices (Turu et al., 2009). CB1R 9 
was cloned in 1990 (Matsuda et al., 1990), 26 years after the isolation of ∆9THC. 10 
CB2Rs were first identified and characterised via polymerised chain reaction 11 
experiments in 1993 (Munro et al., 1993; Onaivi et al., 2006), and were initially thought 12 
to be present only in inflammatory/immune cells; Basavarajappa, 2007b; Munro et al., 13 
1993), although evidence now shows CB2R expression in the brain (Gong et al., 2006; 14 
Onaivi et al., 2006; Van Sickle et al., 2005). Indeed, it is now known that both CB1- and 15 
CB2Rs are widely expressed in the brain (Gong et al., 2006; Moldrich et al., 2000) 16 
although it is postulated that the majority of the functional eCB effects in the CNS are 17 
CB1R mediated (Piomelli, 2003). This receptor is one of the most abundant GPCRs in 18 
the CNS (Herkenham et al., 1991) and its distribution within the mammalian brain 19 
reflects the behavioural effects of cannabinoid administration. For instance, CB1R levels 20 
are particularly high in the cortex, hippocampus, cerebellum and basal ganglia, 21 
correlating with the well-known effects of cannabinoids on cognition, memory and 22 
motor control respectively. (Herkenham et al., 1991; Tsou et al., 1997; for a detailed 23 
review of CB1R localisation see Mackie, 2005). Although also present in the 24 
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hypothalamus, CB1R levels are lower in this brain region than in those mentioned above 1 
(Herkenham et al., 1991; Tsou et al., 1997) which is somewhat surprising considering 2 
the well-known hypothalamic involvement in feeding-related processes (Elmquist et al., 3 
1999). However, a study by Breivogel et al. found that hypothalamic CB1Rs are more 4 
strongly coupled to G-proteins than those in numerous other brain regions including the 5 
cortex and hippocampus (Breivogel et al., 1997), supporting important functional 6 
effects of cannabinoids in this brain region, and suggesting that functional gain 7 
associated with downstream intracellular signalling cascades following CB1R activation 8 
may be of crucial importance. 9 
While CB1- and CB2Rs are thought to mediate the majority of cannabinoid 10 
effects, both exo- and endo-genous cannabinoids also exert effects via other receptors. 11 
In line with this, it has been conclusively demonstrated that the non-psychotropic 12 
exogenous cannabinoids (excluding CBN and ∆9tetrahydrocannabivarin; ∆9THCV) 13 
exhibit almost no affinity for either CB1 or CB2Rs (Petrosino et al., 2009) and must 14 
therefore exert their known pharmacological effects via other routes. A number of 15 
alternative receptor sites are currently being investigated, including GPR55 (Brown et 16 
al., 2001; Pertwee, 2007; Ryberg et al., 2007), GPR119 (Overton et al., 2006) and/or 17 
receptor-coupled or receptor independent ion channels (Oz, 2006) (e.g. transient 18 
receptor potential vanilloid 1; VR1). The former two of these will briefly be reviewed 19 
here since both GPR55 and GPR119 activation have been found to be involved in 20 
aspects of feeding (for reviews of CB1- and CB2R-independent cannabinoid effects see 21 
Brown, 2007; De Petrocellis et al., 2009).  22 
GPR55, first identified by Sawzdargo in human brain and spleen and in rat 23 
brain, spleen and intestine (Sawzdargo et al., 1999; for a gastrointestinal tract review 24 
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see Sanger, 2007), is currently a putative third CBR. Upon activation, GPR55 1 
suppresses M-type K
+
 currents and stimulates phosphatidylinositol 4,5-bisphosphate 2 
(PIP2) -induced Ca
2+
 release from intracellular stores (Henstridge et al., 2009; Lauckner 3 
et al., 2008). While the status of GPR55 as a CBR has been a topic of fierce academic 4 
debate for some years (Petitet et al., 2006), somewhat more compelling evidence has 5 
been presented recently suggesting that it is indeed a CBR (Baker et al., 2006; 6 
Henstridge et al., 2010; Kapur et al., 2009; Lauckner et al., 2005; Pertwee, 2007; Ross, 7 
2009; Ryberg et al., 2007; Staton et al., 2008). Both Baker (Baker et al., 2006) and 8 
Ryberg (using radioligand binding assays in human embryonic kidney (HEK293) cells; 9 
Ryberg et al., 2007) have shown that CP55,940 (a non-selective CBR agonist), but not 10 
WIN55212-2 (a CBR agonist), binds with strong affinity to GPR55; Baker also showed 11 
that AEA, 2-AG and ∆9THC bind to this receptor. Moreover, Ryberg presented further 12 
evidence in the same manuscript suggesting that GPR55 was Gα13 coupled, and that the 13 
comparatively late detection of GPR55 as a possible CBR was because the affinity of 14 
CP55940 for GPR55 binding was 25 times lower than that for CB1R binding. However, 15 
in a similar study Lauckner and colleagues (Lauckner et al., 2005) found that while 16 
∆9THC could activate GPR55 in dorsal root ganglia (DRG) cells, neither WIN55212-2 17 
nor CP55,940 bound to GPR55 in HEK293 and Chinese Hamster Ovary (CHO) cells. 18 
Furthermore the observed effects were blocked by application of SR141716A, a CB1R 19 
specific antagonist, (although not by SR144528, a CB2R specific antagonist), suggesting 20 
that these were CB1R rather than GPR55 mediated. The reasons behind the difference in 21 
CP55,940 binding between the studies by Baker, Ryberg and Lauckner are not 22 
immediately apparent, although Lauckner et al. suggest it may be due to a difference in 23 
GPR55 transfection between the cell types used. Despite such discrepancies, however, 24 
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evidence is mounting for GPR55’s role in the eCB system, as demonstrated for instance 1 
by Kapur and colleagues, who observed AM251 (CB1R inverse agonist) and 2 
SR141716A (a CB1R specific antagonist) binding to GPR55 (Kapur et al., 2009). 3 
Whilst it clearly remains an ‘enigmatic’ receptor (Ross, 2009), research is beginning to 4 
focus on  possible GPR55 based therapies, with recent studies linking it to 5 
neuroinflammation (Pietr et al., 2009), inflammatory and neuropathic pain (Staton et al., 6 
2008) and anorexia (Ishiguro et al., 2010). 7 
Finally, although the identification of GPR119 in 2003 did not initially suggest 8 
links to the eCB system (Fredriksson et al., 2003), later work by Overton and Soga 9 
showing N-oleoylethanolamide (OEA), an AEA analogue, induced GPR119 activation 10 
(Overton et al., 2006; Soga et al., 2005) suggested otherwise. Soga et al. and more 11 
recently Ning et al. observed that GPR119 agonism mediates glucose-dependent insulin 12 
production and release to some extent, as well as increasing intercellular cyclic 13 
adenosine monophosphate (cAMP) accumulation (Ning et al., 2008; Soga et al., 2005). 14 
However, despite findings that GPR119 agonism by OEA suppresses feeding in rats 15 
(Rodriguez de Fonseca et al., 2001), this receptor is unlikely to be involved in centrally 16 
mediated eCB feeding effects as it has been found in the gut (Overton et al., 2006; 17 
Overton et al., 2008). It should nevertheless still be considered when interpreting in vivo 18 
feeding study results and could represent a useful target for anti-obesity therapies 19 
(Hughes, 2009).  20 
Although, as previously mentioned, this review focuses primarily on central 21 
cannabinoid mediated feeding mechanisms, peripheral effects, such as those mediated 22 
by peripheral CBRs or GPR119 add considerable complexity when interpreting in vivo 23 
feeding data. This is particularly true in light of findings describing peripheral CB1R 24 
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expression e.g. in the vas deferens: Pertwee et al., 1996; in the heart, blood vessels and 1 
bladder: Howlett, 2002; the liver and fatty tissue: Cota et al., 2003b; Osei-Hyiaman et 2 
al., 2005), and a potential modulatory role of these peripheral receptors on feeding 3 
behaviour (Gomez et al., 2002). Equally, although it is thought that most of the 4 
functional eCB effects in the brain are CB1R-mediated (Piomelli, 2003), recent work 5 
has suggested some functional expression of CB2Rs in the brain (Onaivi et al., 2006), 6 
particularly at synapses (Morgan et al., 2009), and that these may also be involved in 7 
feeding behaviours (Onaivi et al., 2008). Furthermore, CBR activation in the gut for 8 
example, in terms of gut motility (Izzo et al., 2010), are also likely to have considerable 9 
effects on feeding patterns. As such, it is often difficult, when interpreting in vivo 10 
experimental results, to exclusively assign cannabinoid effects to either central or 11 
peripheral sites of action, or to differentiate between CB1- and CB2-, or indeed non-12 
CBR-mediated effects. Moreover, ligands which produce well-characterised effects at 13 
specific CBRs may also exert effects at other receptor sites, thereby creating unexpected 14 
and potentially unwanted secondary effects. This is well illustrated by SR141716A 15 
(Acomplia/Rimonabant), a well-known selective CB1R antagonist/inverse agonist which 16 
has recently been found by Kapur et al. to agonise GPR55, and which the authors 17 
suggest may have played a part in some of the ‘off-target’ effects that led to its 18 
withdrawal as an anti-obesity drug (Kapur et al., 2009).  19 
There is still much to clarify about how cannabinoids produce their endogenous 20 
effects, and how they might interact with each other in vivo (Ben Amar, 2006; Whalley 21 
et al., 2004). Furthermore, adding to this complexity is the eCB system’s interaction 22 
with other systems, in particular the opioid system which itself has been linked to 23 
appetite regulation for some time (for an early review of opiates and appetite regulation 24 
15 
 
 
see Morley et al., 1982). Indeed, it is now apparent that both the eCB and opioid 1 
systems modulate energy balance, that both systems can modulate food intake 2 
independently and that activation or suppression of both systems together can increase 3 
or reduce food intake to a greater extent than modulation of either system alone (Gallate 4 
et al., 1999; Kirkham et al., 2001c; Solinas et al., 2005). Whilst detailed discussion of 5 
such interactions is beyond the scope of this review, they, along with the numerous 6 
other complexities outlined above, are important factors to consider when looking at, or 7 
indeed conducting and analysing, research on the eCB system and feeding.     8 
 9 
10 
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Cannabinoid-mediated effects upon feeding 1 
The last decade has seen considerable advances in our understanding of eCB-mediated 2 
control of feeding behaviours. Numerous anecdotal reports exist, and the ‘munchies’ 3 
effect has become a well-accepted physiological response to C. sativa consumption, yet 4 
few quantitative reports from this period exist (for a complete review see Kirkham et 5 
al., 2001b). While the ‘classical’ tetrad of cannabinoid effects was defined as decreased 6 
spontaneous motor activity, hypothermia, analgesia and catalepsy (Little et al., 1988), it 7 
was only comparatively recently that ∆9THC was demonstrated to induce hyperphagia 8 
(Williams et al., 1998), an effect clearly linked to CB1R rather than CB2R activation 9 
(Williams et al., 2002b). Since CB2R have only recently been localised to the CNS 10 
(Morgan et al., 2009), and have not been found expressed on feeding pathways, little 11 
research has considered the possible effects that CB2R stimulation may have on feeding. 12 
While a limited number of reports which consider CB2R effects on feeding do exist (e.g. 13 
Onaivi et al., 2008), they have so far presented inconclusive evidence. Furthermore, 14 
possible opioid/cannabinoid and cannabinoid/serotonergic interactions have been 15 
studied, for example by Williams et al., (2002b). Williams demonstrated a functional 16 
relationship between the cannabinoid and opioid systems in the control of appetite, and 17 
notably rejected any serotonergic interaction: upon administration of ∆9THC and either 18 
SR141716A, SR144528, naloxone or dexfenfluramine, Williams observed that while 19 
naloxone could block ∆9THC-mediated feeding increases, dexfenfluramine could not. 20 
Unfortunately, a detailed description of such interactions falls beyond the scope of this 21 
review, although a recent review of the effects of CB/opioid interactions on the 22 
behavioural satiety sequence can be found in Cota et al. (2006). Given the relatively 23 
recent success of treatment with ∆9THC-based CB1R partial agonists (e.g. dronabinol or 24 
17 
 
 
nabilone) and the remaining unmet clinical need in a range of disease states, further 1 
research into pCB-mediated feeding effects is on-going and is reviewed here alongside 2 
classical CB1R agonism and antagonism.  3 
 4 
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Endocannabinoid agonism and its effects on feeding 1 
∆9THC was first shown to exert hyperphagic effects in rats in 1998 (Williams et al., 2 
1998). ∆9THC (0.063-2.0mg/kg) administered orally (per ora; p.o.) to pre-satiated (a 3 
situation in which eCB tone is reduced by the highly palatable prefeed process), adult, 4 
male, Lister hooded rats, at doses >0.5mg/kg significantly increased chow intake 5 
relative to control in the first hour following drug administration. Furthermore, no 6 
significant differences in food intake between control and any ∆9THC doses were seen 7 
over the twenty four hour period following ∆9THC administration. This early study 8 
importantly demonstrated that very low concentrations of orally administered ∆9THC 9 
could substantially change an animal’s motivation to consume; particularly given that a 10 
considerable percentage of the administered drug would have undergone first pass 11 
metabolism as a result of oral administration. Intriguingly, a later study by Avraham 12 
(Avraham et al., 2004) also showed that extremely low ∆8THC doses (a pCB similar to 13 
∆9THC but regarded as more stable; 0.001mg/kg; intraperitoneal; i.p.) increased feeding 14 
in mice. These studies suggest that subtle modulation of the eCB system can be 15 
achieved without the manifestation of the non-specific behavioural side effects 16 
traditionally associated with C. sativa administration (Howlett et al., 2004). The drug 17 
administration routes used by Williams (1998; p.o.) and Avraham (i.p.) do, however, 18 
limit comparison of these results and prevent specific attribution of the effects to central 19 
or peripheral sites.  20 
Exogenous AEA administration (0.5, 1.0, 5.0 and 10.0mg/kg; subcutaneous; 21 
s.c.) has also been observed to induce hyperphagia in pre-satiated rats (Williams et al., 22 
1999). This study demonstrated that AEA administration significantly increased food 23 
intake relative to control in the first hour of testing, in a similar fashion to ∆9THC 24 
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(Williams et al., 1998), but unlike ∆9THC also induced increases in total food intake. It 1 
was proposed that the observed changes in food intake pattern represented an AEA-2 
induced modification in the motivation to feed, since AEA administration caused 3 
feeding to occur far sooner than under control conditions, suggesting a cannabinoid-4 
mediated modulation of normal feeding pathways. Indeed, close inspection of these data 5 
shows that while vehicle-treated animals consumed only small amounts of food in the 6 
first hour of testing, they consumed ten-fold more during the third hour. In slightly later 7 
work, Williams et al. (2002a) used two groups of twelve, male, adult, Lister-hooded rats 8 
which received ∆9THC (0.5, 1.0 or 2.0mg/kg; s.c.) or AEA (0.0, 1.0, 5.0 or 10.0mg/kg; 9 
s.c.) and video recordings of post-administration activity to investigate feeding 10 
behaviours. It became clear that administration of both ∆9THC and AEA significantly 11 
decrease the latency to feeding onset, increase the duration of intake and the number of 12 
meals, but that only AEA increased total intake. Alongside the well-reported increases 13 
in short term chow intake associated with  ∆9THC, these data suggest that ∆9THC and 14 
AEA administration induce their effects by subtly different, and yet to be elucidated 15 
pathways since two distinct changes to feeding behaviours were observed.  16 
Like ∆9THC, extremely low doses of AEA (0.001mg/kg; i.p.) have also been 17 
demonstrated to induce significant increases in food intake in female mice in 18 
experiments which used a 40% diet restriction protocol (Hao et al., 2000). It is 19 
interesting that in a situation when eCB tone would already be increased due to the diet 20 
restriction paradigm used, further slight increases in eCB tone caused by extremely low 21 
doses of AEA induced changes in feeding patterns. Furthermore, it is also interesting 22 
that when Hao and colleagues administered doses of 0.7 and 4.0mg/kg AEA (also i.p.) 23 
in the same set of experiments no significant feeding effects were observed, even 24 
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though, Williams (1999) demonstrated AEA effects at 1.0 and 5.0mg/kg (s.c.). 1 
However, as the authors note, it is particularly difficult to compare Williams et al. 2 
(1999) and Williams et al. (2002a) to Hao et al. (2000) since the experimental 3 
paradigms are almost complete opposites. Indeed, Williams used a prefeed paradigm 4 
followed by s.c. injections in male rats and recorded food intake over a period of six 5 
hours whereas Hao used a diet restricted paradigm followed by i.p. injections in female 6 
mice and recorded daily food intake over a period of one week.  7 
AEA feeding effects were localised to CB1R sites by Williams using a pre-8 
satiated paradigm in 1999. Rats received AEA (0.5, 1.0, 5.0 and 10.0mg/kg; s.c.) and, in 9 
a subsequent trial, AEA (1.0mg/kg; s.c.) plus SR141716A (0.1, 0.5 and 1.0mg/kg; s.c.; 10 
Williams et al., 1999). This demonstrated that AEA significantly increased food intake 11 
relative to control (in a similar fashion to ∆9THC; Williams et al., 1998) and that the 12 
effect could be blocked by SR141716A, thus confirming a CB1R-mediated mechanism 13 
of action for the observed feeding effects. In 2002 the hyperphagia induced by ∆9THC 14 
administration was also localised to CB1R sites (Williams et al., 2002b). Williams first 15 
induced hyperphagia by administering ∆9THC (1.0mg/kg; s.c.) and in further trials 16 
attenuated this effect with the coadministration of SR141716A (0.1, 0.5 and 1.0mg/kg; 17 
s.c.) thereby demonstrating CB1R involvement in this effect. CB2R-mediation was then 18 
discounted as coadministration of ∆9THC (1.0mg/kg; s.c.) and SR144528 (0, 0.05, 0.1, 19 
0.5 and 1.0mg/kg; s.c.) failed to reduce the hyperphagia caused by ∆9THC 20 
administration. 21 
Although Williams et al. (1999) localised AEA-mediated effects on feeding to 22 
CB1R, an effect which one can attribute to CNS receptors, evidence which links 23 
peripheral mechanisms to these effects also exists. Gomez and colleagues (Gomez et al., 24 
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2002) demonstrated that intracerebroventricular (i.c.v.) AEA administration (10.0μg/kg) 1 
and WIN55,212 (10.0μg/kg) increased food intake, but that i.c.v. SR141716A 2 
administration (0.1, 0.4, 2.0 or 10.0μg/kg) did not reduce feeding. In contrast, whilst i.p. 3 
administration of AEA (0.1, 1.0 and 10.0mg/kg) and WIN55,212 (0.4, 2.0 and 4 
10.0mg/kg) similarly increased food intake, i.p. administration of SR141716A (0.3, 1.0 5 
and 3.0mg/kg) reduced feeding. Furthermore, the authors demonstrated that the changes 6 
in feeding patterns they observed were unaffected by a CB2R antagonist (SR144528; 7 
3.0mg/kg; i.p.), principally rejecting the hypothesis that these peripheral effects were in 8 
fact CB2R- as opposed to CB1R-mediated.  SR141716A’s failure to reduce feeding after 9 
i.c.v. but not i.p. administration led Gomez to suggest that CB1Rs must be present in the 10 
periphery and that these peripheral CB1Rs can affect feeding. Gomez supports this 11 
assertion by showing that intestinal AEA levels increase after food deprivation, 12 
suggesting that intestinal endocannabinergic tone plays a role in energy balance. 13 
However, the experimental paradigm used by Gomez did not account for the 14 
concentrations of SR141716A, AEA and WIN55,212 that would be present in the CNS 15 
following i.p. injection or for the considerably different dose ranges used. As such, 16 
while this evidence is suggestive of a peripheral CB1R-mediated role in energy balance, 17 
further experiments are needed to confirm this. 18 
It has been well described that upon administration of an exogenous cannabinoid 19 
agonist endocannabinergic tone will be increased and that alterations to feeding patterns 20 
can then be observed. Furthermore, it has been demonstrated that naturally occurring 21 
eCB concentrations fluctuate in various feeding states. Alongside evidence gathered 22 
using exogenous cannabinoid administration to affect feeding patterns, this elegantly 23 
demonstrates a link between how the natural eCB system modulates feeding patterns 24 
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and how artificial alterations to its state modulate the same patterns. AEA and 2-AG 1 
levels in the rat limbic forebrain, hypothalamus and cerebellum were quantified in three 2 
feeding states; fasted, feeding and satiated (Kirkham et al., 2002). Four groups of 3 
between eight and ten male rats were either: 1) given ad libitum access to food and 4 
sacrificed during a period of low spontaneous feeding; 2) fed with a wet mash for 15 5 
minutes and then sacrificed during feed consumption; 3) fed with a wet mash and 6 
sacrificed once they stopped eating or 4) given a 20% maintenance diet for 24hrs and 7 
sacrificed at the start of their red light cycle the following day. Brain tissue was then 8 
extracted and AEA and 2-AG levels were assessed in the limbic forebrain, 9 
hypothalamus and cerebellum. AEA and 2-AG levels were significantly elevated by 10 
food deprivation in the limbic forebrain while 2-AG concentration was significantly 11 
reduced in the hypothalamus during the feeding state but significantly increased during 12 
the deprived state. Since 2-AG levels were increased in the limbic forebrain and 13 
hypothalamus, and AEA levels were significantly increased in the limbic forebrain, it 14 
appears that elevated eCB levels in important reward-related brain areas during food 15 
deprivation play a role in motivating animals towards food. The reduction of 2-AG 16 
levels in the hypothalamus during feeding suggests that 2-AG is actively suppressed 17 
during feeding to facilitate satiation. Such data suggest subtly differing roles for AEA 18 
and 2-AG in feeding cycles. 19 
Further experiments published in the same manuscript revealed that 2-AG (i.c.v. 20 
into the nucleus accumbens at 0.5 and 2.0μg) could significantly increase food intake 21 
over a one hour period while coadministration of SR141716A (0.5mg/kg; s.c. plus 22 
0.5μg 2-AG; i.c.v.) could almost fully attenuate this effect, thereby demonstrating CB1R 23 
mediation. The increases in food intake seen in Kirkham et al. (2002) are comparable to 24 
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the similar studies performed by the same group following ∆9THC administration 1 
(Williams et al., 2002b; Williams et al., 1998), however are considerably different from 2 
a feeding study which administered AEA (Williams et al., 1999). Indeed, AEA 3 
(1.0mg/kg; s.c.) effects were observed over four hours and during the first hour 4 
significantly increased intake by a factor of approximately two, as well as significantly 5 
elevating food intake over the entire four hour period. In contrast, 2-AG (0.5 and 6 
1.0μg/kg; i.c.v.) significantly increased food intake by factors of nine and seven, 7 
respectively, over a one hour period. However, it is important to note that in this 8 
instance 2-AG administration was i.c.v. and AEA administration was s.c., and it is 9 
possible that AEA-mediated feeding increases would have been larger had 10 
administration been i.c.v. Given the strong anatomical connections between the nucleus 11 
accumbens shell and the hypothalamus (Stratford et al., 1999) and the importance of the 12 
hypothalamus in the integration of feeding pathways (Maccarrone et al., 2010) these 13 
data represent a demonstration that modulation of this pathway can have profound 14 
feeding effects.  15 
As considerable differences in eCB levels in the limbic forebrain were seen 16 
during various feeding states in (Kirkham et al., 2002) and because the limbic forebrain 17 
is traditionally associated with reward processing, possible interactions between the 18 
eCB and opioid systems were then considered by Williams and Kirkham (Williams et 19 
al., 2002b). It was demonstrated that ∆9THC-induced hyperphagia could be attenuated 20 
by the opioid antagonist naloxone. This proves a link between opioid food reward 21 
processing and the eCB system. These experiments are also exciting in terms of putative 22 
anti-obesity treatments. Indeed, it has been reported that in obese humans, eCB levels 23 
are elevated by up to 52% (Engeli et al., 2005); as such experiments which artificially 24 
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elevate eCB activity using food-restriction paradigms are particularly valuable since 1 
they more accurately model the human obese condition. Moreover, since in both the 2 
food deprived and obese states eCB levels are increased, this further supports the theory 3 
that eCB dysfunction plays an important part in human obesity. Further studies which 4 
directly compared AEA and 2-AG-induced feeding effects (both centrally and 5 
peripherally administered) would be extremely useful. It would be equally compelling 6 
for further work to consider fully the putative effects of peripheral cannabinoid 7 
receptors on feeding behaviours, for example in terms of gut motility.  8 
Given the previously discussed alterations to eCB concentrations in the limbic 9 
forebrain, an area traditionally associated with reward processing and well documented 10 
opioid/cannabinoid interactions, it is clear that the changes to behavioural patterns 11 
observed during cannabinoid administration are due to changes in reward levels. 12 
Therefore, cannabinoid agonist effects on the consumption of different types of 13 
rewarding ingesta, such as sweet versus fatty foods, was addressed in a study by Koch 14 
(2001). Here, ∆9THC (0.0, 0.5, 1.0 and 2.5mg/kg; i.p.) was administered to rats 15 
receiving either control (chow), high fat (HF) or high fat plus sugar (HFS) diets and 16 
food intake was recorded over 24 hours post-injection. After the first hour, 0.5 and 17 
1.0mg/kg ∆9THC significantly increased food intake versus control within the HF diet 18 
group only, while doses of 2.5mg/kg had no significant effects on intake in any group. 19 
However, overall food intake during the first hour was significantly greater in the HF 20 
group than in either the control chow or HFS groups. During the second hour of testing, 21 
the 0.5 and 1.0mg/kg ∆9THC doses significantly increased intake versus control in all 22 
three groups with 1.0mg/kg causing the largest increases. This dose also induced a 23 
significantly greater intake increase in the HF (but not in the HFS) than in the control 24 
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chow group, although overall food intake across all doses was significantly greater in 1 
both the HF and HFS groups, relative to the control chow group. Finally in the fourth 2 
hour, unlike previous feeding studies employing ∆9THC which showed effects lasting 3 
fewer than four hours, ∆9THC doses of 1.0mg/kg still induced significant increases in 4 
consumption compared to vehicle in the HF and HFS diet groups. 5 
The increases in intake seen at lower dose levels by Koch appear comparable 6 
(though reduced) to those previously reported (Williams et al., 1998) and support a 7 
cannabinoid-mediated stimulation of intake (Williams et al., 1999; Williams et al., 8 
1998), although the non-significant effects of 2.5mg/kg ∆9THC remain unexplained, 9 
particularly as no changes to motor coordination or the appearance of tetrad effects were 10 
reported for this dose. Therefore, it is clear from these results that eCB system 11 
stimulation induces greater increases in the intake of highly fatty food-types (HF) than 12 
other, less calorific or more palatable, diets (HFS). Previous work by Arnone et al. 13 
(1997) and Simiand et al. (1998) (this work is fully discussed in ‘Endocannabinoid 14 
antagonists and their effects on feeding’) would suggest that the HFS intake should also 15 
have been increased by ∆9THC administration. Indeed, ∆9THC administration induced 16 
similar intake increases in the HFS and HF diet groups but only after the fourth and 17 
twenty-fourth hours of testing. These data could suggest that the eCB system is 18 
involved more strongly in increasing the motivation to consume high fat foods and that 19 
this effect manifests more quickly than eCB increases due to other ‘bland’ food types. 20 
From the perspective of evolution, an increased motivation to consume high fat foods is 21 
obvious and as such it is reasonable to suggest from this data that the eCB system is 22 
intimately involved in this process.  23 
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In a later study specifically designed to look at cannabinoid modulation of 1 
palatability, Higgs et al. (2003) tested the effects of various cannabinoid receptor 2 
ligands on consumption of a 10% sucrose solution in rats. In this test ∆9THC or AEA 3 
(0.5, 1.0 or 3.0mg/kg in both cases; i.p.) but not 2-AG (0.2, 0.5 and 2.0mg/kg; i.p.) 4 
significantly increased sucrose solution consumption. By analysing lick patterns using 5 
the mathematical model of ingestive control proposed by Davis et al. (1977), this effect 6 
was ascribed to a cannabinoid-induced increase in perceived palatability. The lack of 7 
significant 2-AG-induced effect is surprising, since both 2-AG and AEA are partial 8 
agonists at CB1R sites (although it has been suggested that 2-AG is the main ligand 9 
associated with CB2R sites; Sugiura et al., 1999; Sugiura et al., 2000), and because of 10 
the significant effects observed by Kirkham et al., (2002). Higgs suggests that different 11 
speeds at which the exogenous and endogenous ligands act, coupled with the probable 12 
lack of 2-AG brain penetration (due to the route of administration), can explain the 13 
reduced effects of AEA compared to ∆9THC and could, to some extent, shed light on 14 
the limited effects of 2-AG. Administration of SR141716A alone was also tested (0.5, 15 
1.0 and 3.0mg/kg; i.p.) by Higgs, and found to elicit a dose-dependent decrease in 16 
consumption, thus linking the observed effects to modulation of endogenous CB1R 17 
activation. Yet, it could be argued that the dose-dependent decreases in consumption 18 
induced by SR141716A seen here were caused by a reduction in eCB tone of which 2-19 
AG plays a part, and as such it remains impossible to discount any effects of 2-AG 20 
acting at CB2R sites on this process. This finding demonstrates that the eCB system 21 
must have an active effect upon appetite and feeding since CB1R blockade alone, 22 
without co-administration of a cannabinoid agonist (c.f. Gallate et al., 1999; Williams et 23 
al., 1999), significantly reduces consumption. Considering the works of Koch (2001), 24 
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Gallate et al. (1999) and Williams et al. (1999) it can be suggested that eCB system 1 
stimulation upregulates the palatability of high calorie, low palatability foods and 2 
conversely, reducing endocannabinergic tone diminishes perceived palatability. This 3 
could explain why in Koch’s work the HF diet intake was increased above HFS diet as 4 
it was both palatable and calorie-rich.  5 
In a very recent study Yoshida and colleagues (2010) administered AEA and 2-6 
AG to both wild type and CB1R knock-out mice. They observed that AEA and 2-AG 7 
preferentially increased taste responses to sweet rather than salty, sour, bitter or umami 8 
(a Japanese term for a meaty or savoury taste) flavours in the chorda tympani nerve, 9 
fungiform taste buds and during a short-term lick response test. Furthermore, they did 10 
not observe this effect in their knock-out mice, hence linking this effect to CB1R. Given 11 
their i.p. route of administration, the authors have suggested a peripheral effect, 12 
alongside the well described central effect, of eCBs on taste. In comparison with the 13 
work of Higgs et al (2003) who found 2-AG to have little effect on palatability in a 14 
progressive lick-based paradigm, and considering that both studies used i.p. 15 
administration and observed peripheral taste responses, it is not immediately apparent 16 
why different eCBs are identified as the principal modulators of taste.   17 
In earlier taste reactivity studies, Gallate et al. (1999) presented rats with various 18 
concentrations of ‘beer’ (<0.5%, 2.7% or 4.0% ethanol solutions) or an 8.6% sugar 19 
solution, and their motivation to consume these substances was measured using a lick-20 
based progressive ratio paradigm. In order to assess CB1R involvement, animals were 21 
treated with either vehicle, the CB1R agonist CP55,940 (10.0, 30.0 or 50.0μg/kg; i.p.), 22 
CP55,940 (30.0μg/kg; i.p.) plus SR141716A (1.5mg/kg; i.p.), or naloxone (2.5mg/kg; 23 
i.p.) plus CP55,940 (30.0μg/kg; i.p.). This drug regime therefore also examined 24 
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potential interactions between the cannabinoid and opioid systems. In agreement with 1 
previous research, CP55,940-treated animals exhibited a significant trend whereby 2 
increasing dose led to increases in both beer and sucrose solution consumption. 3 
SR141716A-induced CB1R blockade during CP55,940 treatment attenuated this effect, 4 
reducing beer solution intake to levels that did not differ from vehicle treatments. 5 
Furthermore, CP55,940 plus naloxone administration significantly reduced beer intake 6 
to approximately 50% of vehicle intake, confirming a strong interaction between CB1 7 
and opioid receptors in the control of alcohol consumption. This study demonstrated 8 
that CB1R activation could induce significant increases in palatable solution intake 9 
when compared to vehicle-treatments, and that this effect was attenuated by CB1R 10 
antagonists; further supporting the theory of CB1R involvement in perceived 11 
palatability. 12 
In 2005 and 2007 Jarrett et al. (Jarrett et al., 2005; Jarrett et al., 2007) 13 
demonstrated that the eCB system mediated the perceived palatability of sweet and 14 
bitter tastes. In trials using adult, male Sprague-Dawley rats, ∆9THC (0.5mg/kg; i.p.), 15 
∆9THC (0.5mg/kg; i.p.) plus SR141716A (2.5mg/kg; i.p.) or AM251 (1.0mg/kg; i.p.), or 16 
AM251 (1.0mg/kg; i.p.) alone were administered via intraoral cannulae and the 17 
orofacial reactions to intraoral administration of either sucrose (2, 10 and 32%), or 18 
quinine (0.01 or 0.05%) solutions were recorded. ∆9THC increased the perceived 19 
palatability of the sucrose solution, an effect attenuated in animals treated with ∆9THC 20 
plus SR141716A (Jarrett et al., 2005). In the later study, ∆9THC reduced aversiveness 21 
to 0.05% quinine solution, an effect that was blocked by coadministration of AM251 22 
(Jarrett et al., 2007). The authors suggest that their results indicate that increases in 23 
CB1R responsiveness could be involved in a general upregulation of the ingesta 24 
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palatability. In further experiments during the same two studies, Jarrett and colleagues 1 
also demonstrated that SR141716A administration alone does not reduce perceived 2 
palatability (Jarrett et al., 2005) but AM251 administration enhances aversiveness 3 
(Jarrett et al., 2007). This may suggest that the increased palatability of sweet food can 4 
activate the eCB system and upregulate eCB tone. However, in the case of bitter tasting 5 
food, when eCB tone would not be increased by the low palatability of the food, CB1R 6 
antagonism can then reduce the perceived palatability of the food further.   7 
Further supporting this palatability hypothesis, it has recently been demonstrated 8 
that, under a reinforced learning paradigm which included food type (normal lab chow, 9 
chocolate pellets or fat-enriched pellets) selection as an experimental variable, mice will 10 
select the sugar rich, highly-palatable food type or fatty foods over standard food after 11 
∆9THC (1.0mg/kg; i.p.) administration (Barbano et al., 2009). Since, the chocolate-12 
enhanced pellets used in this study had the same calorific content as the standard food 13 
pellets also employed while the fat enriched pellets contained approximately 66% more 14 
calories per gram but no added chocolate, it can be observed that ∆9THC administration 15 
increased the palatability of fatty foods to a level comparable to that of sweet foods.  16 
The conclusion that the eCB system exerts a level of control over palatability 17 
reward is well supported. It has been shown that increased eCB tone increases the 18 
palatability of sweet liquids (Gallate et al., 1999; Higgs et al., 2003), bland fatty foods 19 
(Koch, 2001) or even aversive, bitter liquids (Jarrett et al., 2005; Jarrett et al., 2007). 20 
Indeed, eCB levels change naturally reflecting the current feeding state, and it is this 21 
basal tone that can be altered with the application of CB1R ligands. Furthermore, the 22 
meal pattern changes induced by stimulation of the eCB system are also well 23 
understood. ∆9THC administration has been demonstrated to reduce the latency to 24 
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feeding onset in periods of reduced endocannabinergic tone and has also been shown to 1 
increase meal sizes. If we consider appetitive behaviours as those that regulate the 2 
latencies to meal onset and consummatory behaviours as those that regulate the size of 3 
any given meal, what becomes clear from these data is that modulation of the eCB 4 
system can affect consummatory and/or appetitive behaviours and that these different 5 
behavioural changes can be manipulated individually. For example, in the work of 6 
Williams et al. (2002a), a distinct separation was seen between the AEA and ∆9THC 7 
groups in terms of feeding behaviour. In this instance, AEA administration produced 8 
effects comparable to ∆9THC: AEA significantly reduced the latency to feeding onset, 9 
whilst also increasing the number of eating bouts. AEA administration also increased 10 
meal duration and the duration of the longest bout versus control conditions. However, 11 
unlike ∆9THC, AEA induced significant increases in total intake over the test period. 12 
Given these data it can be clearly seen that the changes to feeding patterns (either in 13 
gross terms or in terms of palatability levels) are due to changes to reward processing. 14 
Indeed, the decreased latency to feeding onset and the increased size and length of 15 
meals thereafter coupled with increased lick responses can all be linked to increased 16 
reward.  17 
 18 
 19 
20 
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Endocannabinoid antagonism and its effect on feeding 1 
Alongside the well documented hyperphagic effects of ∆9THC administration there is 2 
comprehensive complimentary evidence which details the effects of reducing eCB tone 3 
on feeding behaviours. Indeed the use of CB1R antagonist-based studies represents an 4 
elegant way to study the effects of basal eCB tone on physiological feeding 5 
mechanisms. This is particularly true as many CBR antagonists are highly selective. In 6 
1997 Arnone (Arnone et al., 1997) and colleagues performed a comprehensive set of 7 
experiments which revealed the changes to feeding behaviours induced by CB1R 8 
blockade by the administration of SR141716A (0.0, 0.1, 0.3, 1.0 or 3.0mg/kg: i.p.). In 9 
experiments which studied either intake of sucrose pellets, intake of a 5% sucrose 10 
solution or a 10% ethanol solution, Arnone demonstrated that eCB tone plays an 11 
important role in the perceived appetitive values of both alcohol and sugar. Firstly, 12 
Arnone and colleagues measured the weight of food consumed in 30min open field tests 13 
where food-restricted male, Wistar rats (a situation in which one would expect eCB tone 14 
to be increased by the food restriction (Kirkham et al., 2002)) had access to either 15 
sucrose pellets and standard lab chow or standard lab chow alone after SR141716A 16 
administration. The quantity of sucrose pellets consumed by rats was reduced from 17 
3.1±0.4g under control conditions to 1.0±0.4g after the 3.0mg/kg SR141716A dose in a 18 
dose-dependent fashion; furthermore, the two highest doses of SR141716A induced 19 
significant reductions when compared to control intakes. Standard chow intake was 20 
unaffected. However, when Arnone repeatedly administered 3.0mg/kg SR141716A in 21 
mice with a predisposition to alcohol consumption over four, six hour test periods in 22 
one day, SR141716A induced a suppression of ethanol intake. Secondly, rats (male, 23 
Sprague-Dawley) were given access to a 5% sucrose solution for a period of four hours 24 
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without access to food and water. As a control experiment another group of rats was 1 
given access to water for the same test period. Sucrose solution intake was significantly 2 
reduced by the two highest doses of SR141716A and a significant dose-dependent 3 
reduction in sucrose solution intake was apparent. Water intake was unaffected by 4 
SR141716A administration at any dose. Thirdly, Arnone tested the effect SR141716A 5 
had on ethanol consumption in male C57BL6 mice; once again administration of either 6 
1.0 or 3.0mg/kg SR141716A induced significant reductions in consumption versus 7 
control-treatment and a significant dose-dependent effect was apparent for the entire 8 
dose range. Water-only tests were used as a control, as per the 5% sucrose solution test, 9 
and no effect of SR141716A was apparent. These three experiments demonstrate that 10 
the eCB system plays an active role in the control of the appetitive value of sweet and 11 
alcoholic ingesta. Indeed, such experiments prove that the eCB system must have a 12 
constantly active basal tone as antagonists applied to an inactive system would induce 13 
no behavioural changes alone. Furthermore, given the selectivity of SR141716A we can 14 
be confident that this effect is localised to CB1R sites.  15 
Reductions in eCB tone induced by the administration of SR141716A (0.0, 1.0 16 
and 3.0mg/kg; p.o.) were extended to marmosets in 1998 by Simiand (Simiand et al., 17 
1998). Marmosets were habituated to a high-sugar mash (HSM; 33% sugar, 67% milk 18 
and cereal) and after habituation administered SR141716A twice a week; their food 19 
(either HSM or standard diet) intake was then observed for a period of six hours. 20 
Administration of the 3.0mg/kg dose induced significant reductions in HSM intake 21 
versus control-treatments after one, three and six hours while the 1.0mg/kg dose only 22 
reduced HSM intake versus control-treatments during hours one and three. Notably 23 
standard diet intake was unaffected by SR141716A administration with the exception of 24 
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a significant increase in intake seen during hour six. These data demonstrate that 1 
SR141716A can preferentially reduce intake of sweet, highly palatable food, versus 2 
bland food. This suggests that eCB tone is responsible for increasing the appetitive 3 
values of high-sugar foods under normal physiological conditions. Indeed, as previously 4 
discussed, such work has been supported by later experiments which showed 5 
SR141716A administration could reduce the reward associated with sucrose solutions 6 
(Higgs et al., 2003). Since Arnone et al. (1997) and Simiand et al. (1998), together, 7 
used two strains of rats, one strain of mouse and one type of primate and observed 8 
similar results, it can be suggested that the effects of the eCB system are similar across 9 
species. However, the work of Arnone and Simiand did not consider a high fat diet 10 
alternative to the high-sugar foods they used, and they only antagonised the eCB system 11 
over a shorter period of time. It is worthwhile comparing the works of Arnone and 12 
Simiand to that of Williams and colleagues. Indeed, while Williams observed CB1R 13 
stimulation to increase feeding, and that this effect could be blocked by 14 
coadministration of SR141716A, Arnone and Simiand demonstrated a basal 15 
endocannabinergic tone which when blocked with SR141716A alone could reduce 16 
feeding. Furthermore, as discussed, the eCB system has been demonstrated to alter its 17 
activity level dependent on feeding state (e.g. deprived of food versus eating; Kirkham 18 
et al., 2002). Taken together, these studies demonstrate that eCB tone is a powerful 19 
effector of perceived hunger and that feeding reduces endocannabinergic tone in the 20 
same way as blocking CB1R sites in the CNS. 21 
∆9THC-induced effects on high fat versus high sugar foods were well described 22 
by Koch in 2001. However, only recently were antagonist studies used to facilitate the 23 
understanding of the role of CB1R alone in the selection and consumption of highly 24 
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fatty or sweet foods. In 2007, a study by Thornton-Jones et al. (2007) examined the 1 
effects of SR141716A-induced CB1R blockade on consumption of sweet (10% sucrose) 2 
or fatty (10% intralipid) solutions and analysed the lick-based response in a way similar 3 
to Higgs et al. (2003). Appealingly, this paradigm also compared the hypophagic 4 
SR141716A effects with those induced by behavioural manipulations designed to 5 
reduce either motivation to feed (pre-feeding) or food palatability (addition of quinine to 6 
the intralipid solution and reduction of sucrose concentration to 5%) which, combined 7 
with the lick-based microstructure analysis, allowed for more detailed interpretation of 8 
the results. Supporting previous findings, this study demonstrated that SR141716A 9 
treatment reduced both sucrose and intralipid solution intake, and microstructure 10 
analysis revealed that these reductions were due to decreased perceived palatability of 11 
ingesta. However, whilst these significant reductions were induced by both 1.0mg/kg 12 
and 3.0mg/kg SR141716A for the intralipid solution, only 3.0mg/kg SR141716A 13 
significantly reduced sucrose solution consumption. Furthermore, reduced lick duration 14 
of intralipid solution observed after drug administration led the authors to suggest that 15 
the SR141716A-induced reduction in consumption of this solution was a result of a 16 
decrease in motivation to feed, as well as an effect on perceived palatability. In contrast, 17 
reductions in sucrose solution intake were less pronounced than those seen for the 18 
intralipid solution, suggesting that eCBS may be more strongly implicated in 19 
consumption of highly calorific than sweet, palatable food-types. Taken alone, this work 20 
suggests that the eCB system can play its role in energy homeostasis via modulation of 21 
the motivation to consume fatty foods specifically; this long term effect may be due to 22 
changes in meal patterning over the shorter term, particularly with respect to the control 23 
of fat intake. Indeed, the work of Thornton-Jones further supports the findings of 24 
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Arnone et al. (1997), Simiand et al. (1998) and Koch (2001), as previously discussed, 1 
and strengthens the link between CB1R activation and the control of feeding. 2 
Using a different experimental approach, a recent study by Mathes et al. (2008) 3 
also addressed these issues, and provided further support for eCB system involvement 4 
in the specific consumption of highly fatty and/or sweet foods. A ‘dessert protocol’ was 5 
employed, whereby rats were given ad libitum access to a wet mash diet made from 6 
standard laboratory chow in addition to simultaneous but time limited access to a 7 
‘dessert’ diet high in fat and sugar. Vitally, this methodology gave rats a choice between 8 
two different diets, allowing within-group analysis of diet selection. eCB system 9 
involvement in the consumption of these two different food-types was assessed by 10 
administration of either of the CB1R antagonists, SR141716A (1.0mg/kg; i.p.) or 11 
AM251 (0.3, 1.0 or 3.0mg/kg; i.p.) 30min prior to dessert access. Both compounds 12 
significantly reduced caloric intake over a 24 hour period, but this effect was due to a 13 
significant decrease in the consumption of the high fat and sugar diet only, with no 14 
effect on the consumption of the standard chow. When considered alongside Arnone et 15 
al. (1997), Koch (2001), Simiand et al. (1998) and Thornton-Jones et al. (2007), these 16 
findings suggest that CB1R-mediation of intake not only modulates intake of fatty food 17 
more that sugary food, but does so in a preferential fashion. Unfortunately, although 18 
Mathes et al., in the earlier stages of this study, compared the consumption of the high 19 
fat and sugar diet with another diet high in sugar only, the effects of CB1R blockade on 20 
this sugar-only diet were not examined. 21 
While the use of the previously discussed antagonists has been shown to reduce 22 
feeding in a number of models, there is considerable on-going research looking for 23 
novel compounds which perform similar actions. Such research is performed to further 24 
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our understanding of the eCB system and its ligands, whilst also searching for new anti-1 
obesity drugs (for examples please see PSNCBAM-1, Horswill et al., 2007; AM4113, 2 
Sink et al., 2007; O-2050, Gardner et al., 2006; MK55-96, Yan et al., 2010; and MK-3 
0364, Fong et al., 2007). While, O-2050 was found to induce significant reductions in 4 
motor coordination, which may have been the cause for its effects on feeding 5 
behaviours, PSNCBAM-1, AM4113 and MK-5596 have been demonstrated to reduce 6 
short term intake and reduce body weight in animal models without apparent side 7 
effects. Further work using these novel agents would benefit from the inclusion of meal 8 
patterning analysis as this would allow the study of appetitive and/or consummatory 9 
behaviours, as well as effects on perceived palatability; such an analysis may shed more 10 
light on eCB mediation of feeding behaviours. 11 
 12 
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Non-∆9THC phytocannabinoid effects on feeding 1 
Very recently it has been suggested that non-∆9THC pCBs can also modulate rodent 2 
feeding patterns (Farrimond et al., 2010a; Farrimond et al., 2010b) and induce different 3 
changes than ∆9THC, without any apparent non-specific behavioural effects. Before 4 
2009 there had been a limited number of studies which demonstrated non-∆9THC pCB-5 
mediated feeding effects. Unfortunately these studies were either unrepeated or 6 
contradictory. Sofia and Knobloch (1976) reported that the CB1R agonist CBN reduced 7 
intake in rats, an effect yet to be repeated, and that CBD also reduced feeding in rats. 8 
However, Wiley et al., (2005) reported that CBD administration had no effect on food 9 
intake in mice, a result repeated by Riedel (2009) who observed only a small, non-10 
significant reduction in food intake and weight gain, also in mice. It should be noted 11 
that the dose ranges used by Sofia, Knobloch and Wiley are considerably higher than 12 
those used by Farrimond and colleagues and, given the well described bi-phasic dose 13 
effects of CB1R activation (Glick et al., 1972) on feeding, this may explain the 14 
differences in observed effect patterns. Work in our laboratory has demonstrated that a 15 
range of pCBs may have significant effects on feeding patterns. Thirty-six pre-satiated, 16 
male, Lister-hooded rats received a purified, C. sativa-derived ∆9THC (hereafter 17 
purified ∆9THC), a synthetic ∆9THC and a high-∆9THC standardised botanical drug 18 
substance (BDS), similar in composition to that used in Sativex and containing a typical 19 
array of non-∆9THC pCBs (high-∆9THC BDS; all treatments were dose matched for 20 
∆9THC content; 0.00, 0.34, 0.67, 1.34 and 2.68mg/kg; p.o.; Farrimond et al., 2010a). 21 
Synthetic and purified ∆9THC administration induced classical ∆9THC hyperphagia in 22 
this study: the latency to the first meal was reduced and both the first hour intake and 23 
first meal duration were increased versus vehicle treatments. Intriguingly, the effects of 24 
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the high-∆9THC BDS administered showed significantly reduced hyperphagia in 1 
comparison. These results suggested that the combination of pCBs (and, potentially, 2 
non-cannabinoid components) in the high-∆9THC BDS attenuated the hyperphagic 3 
effects of ∆9THC. Given the constituents of the high-∆9THC BDS, (∆9THC; 67.0%, 4 
Cannabigerol (CBG); 1.7%, Cannabichromene (CBC); 1.6%, CBN; 1.5%, ∆9THCV; 5 
0.9%, ∆9tetrahydrocannbinolic acid (∆9THCA); 0.3%, CBD; 0.3% and Cannabitriol 6 
(CBO); 0.2%) it is possible that the pCBs present could have affected feeding 7 
synergistically, or that at least one pCB modulated the ∆9THC-induced hyperphagia. 8 
Indeed, the high-∆9THC BDS used in Farrimond et al., (2010a) contained known CB1R 9 
antagonists (∆9THCV, Dennis et al., 2008; Ma et al., 2008; Thomas et al., 2005) in 10 
addition to modulators of Ca
2+
 homeostasis (CBD; Ryan et al., 2009) and CBN (Rao et 11 
al., 2006); which could modulate eCB levels. However, these results do not preclude the 12 
possibility that non-cannabinoid material also present in the high-∆9THC BDS also 13 
contributed to the observed behavioural effects.  14 
Consistent with these results we have also demonstrated that non-∆9THC pCBs 15 
can affect feeding when co-administered with sub-effective concentrations of ∆9THC 16 
(Farrimond et al., 2010b; please also see Riedel et al., 2009 for non-∆9THC pCB-17 
induced hypophagia fully discussed below). Ten, pre-satiated, adult, male, Lister-18 
hooded rats received a low-∆9THC standardised BDS (low-∆9THC BDS; 0.0, 0.5, 1.0, 19 
2.0 and 4.0mg/kg; p.o.) containing only 6.9% ∆9THC, alongside 14.2% other pCBs. 20 
Conversely, at these concentrations, rather than having no effect on feeding (as it might 21 
be expected, given the use of a prefeed paradigm with an extremely low dose of ∆9THC 22 
and pCBs that have previously been shown to reduce ∆9THC-mediated hyperphagia), 23 
the low-∆9THC BDS significantly increased chow intake during the first hour, by 24 
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significantly reducing the latency to the first contact with food for the highest doses 1 
versus vehicle-treatments. These reductions in meal one latency mirror those previously 2 
demonstrated for considerably higher concentrations of pure ∆9THC (Farrimond et al., 3 
2010a; Williams et al., 1998). Furthermore, while the latency to the first meal was 4 
significantly reduced, the size and duration of this meal was unaffected. Therefore, we 5 
suggested that the ratio of non-∆9THC pCBs present in the low-∆9THC extract 6 
significantly increased appetitive (but not consummatory behaviours), since the 7 
concentrations of ∆9THC present were between two- and ten-fold lower than those 8 
previously demonstrated to induce hyperphagia (Farrimond et al., 2010b). 9 
When these two studies are considered together (Farrimond et al 2010a and 10 
2010b), a number of suggestions can be made: firstly, since the observed effects of the 11 
non-∆9THC components of the extracts administered reduced hyperphagia when 12 
presented in one ratio and increased hyperphagia when presented in a different ratio, it 13 
is highly unlikely that the plant matter also present was responsible for these effects, 14 
given that its content did not change between the two tests. Secondly, it is possible that 15 
the pCBs present in both studies did not act in isolation such that more than one 16 
compound induced the observed effects. Thirdly, these effects could involve non-CBR 17 
dependent pathways since several of the non-∆9THC pCBs present are known to act via 18 
mechanisms only partially connected to CBR (see Izzo et al., (2009) for review). 19 
Finally, these results give further credence to the already well supported therapeutic 20 
potential of non-∆9THC pCBs for the treatment of energy balance disorders. Indeed, 21 
non-∆9THC pCB-based treatment may prove more tolerable than ∆9THC treatment 22 
alone (e.g. Nabilone) due to the absence of psychotropic side effects associated with 23 
non-∆9THC pCBs. 24 
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Whilst a definitive mechanism underlying the findings reported by Farrimond et 1 
al., (2010a and b) remains unknown, the naturally occurring pCB and CB1R neutral 2 
antagonist ∆9THCV, which was also present in the extracts employed in Farrimond et 3 
al., has been considered alone and shown to exert hypophagic actions (Riedel et al., 4 
2009). Indeed, given the difficulties associated with the use of the highly specific and 5 
potent CB1R antagonist/inverse agonist SR141716A in the clinic, the use of ∆
9
THCV, 6 
as a neutral antagonist, to reduce food intake may be of therapeutic value. Riedel et al. 7 
(2009) demonstrated that purified ∆9THCV (3.0, 10.0 and 30.0mg/kg; i.p.) significantly 8 
reduced chow intake over a period 12 hours and induced weight loss in male C57BL6 9 
mice. Subsequent treatment with extremely low ∆9THCV BDS doses (which contained 10 
between 0.1 and 0.3mg/kg ∆9THC) failed to induce changes to feeding patters; however 11 
the ∆9THC quantities presented were within the range previously observed to affect 12 
meal patterning in rats (Farrimond et al., 2010). Unfortunately, meal microstructure was 13 
not analysed in this study. In a further experiment, Riedel hypothesised that if CBD 14 
(10.0mg/kg; i.p.) were to be co-administered with these very low ∆9THCV BDS doses, 15 
the effects of the present ∆9THC would be antagonised, and the hypophagic properties 16 
previously induced by purified ∆9THCV would therefore emerge. However, the 17 
evidence for in vivo antagonism of ∆9THC by CBD has so far only been demonstrated  18 
in a memory task (Fadda et al., 2004), and Riedel observed no significant effects on 19 
feeding or weight change following CBD co-administration. The authors suggest that 20 
this lack of effect may also be attributed to other pCBs, present in his extract, or simply 21 
because the concentrations of ∆9THCV administered were too low. However, Riedel 22 
recorded all feeding data during the light phase of the rats’ day during which time little 23 
feeding typically occurs. Furthermore, it is also possible that the experimental paradigm 24 
41 
 
 
used was not optimised for the observation of hypophagia. For instance, introducing 1 
food-deprivation prior to dosing could accentuate possible differences between control 2 
and conditions measurements, thereby rendering the experimental paradigm more 3 
sensitive to ∆9THCV-mediated reductions in feeding. While, Riedel has confirmed that 4 
purified ∆9THCV can reduce food intake in mice, further experiments which use more 5 
sensitive paradigms and analyse meal microstructure after ∆9THCV BDS administration 6 
may prove useful in fully understanding Riedel’s data. 7 
The work discussed throughout this manuscript demonstrates that some pCBs 8 
can alter appetitive and consummatory behaviours separately (e.g. Higgs et al., 2003). 9 
As such if it were possible to use at least one non-∆9THC pCB to modulate 10 
consummatory behaviours (to increase or decrease the quantity consumed during a 11 
natural eating event) rather than inducing immediate short term post-administration 12 
hunger (the ‘munchies’, a colloquial term meaning increased hunger normally due to 13 
smoking cannabis recreationally) it may be possible to produce a C. sativa-based 14 
medicine which could control absolute intake quantity. Even though the mechanisms by 15 
which the eCB system modulates palatability and therefore diet selection remain 16 
unclear, direct effects on diet selection caused by cannabinoid administration have also 17 
been demonstrated. Given the presented data which suggests that increased eCB tone 18 
leads to increased selection of fatty foods over sweet foods, it is a possibility that non-19 
psychotropic pCBs could also be used to modulate diet selection i.e. to reduce fatty food 20 
palatability in obesity. Indeed, putative anti-obesity treatments using pCBs are of great 21 
interest. Equally, while some pCBs have been shown to induce significant reductions in 22 
food intake and in some cases reduce body weight (e.g. ∆9THCV), little research is 23 
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currently considering possible mechanisms by which intake and body weight may be 1 
increased, which would be valuable in the treatment of anorectic disorders.  2 
 3 
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Conclusions  1 
A considerable quantity of characterisation work has been performed on ∆9THC-2 
mediated feeding effects, but the specific roles of other pCBs remain less well 3 
understood. Work in our laboratory and others suggests that non-∆9THC pCBs can have 4 
profound effects on feeding behaviours (Farrimond et al., 2010a; Farrimond et al., 5 
2010b; Riedel et al., 2009; Sofia et al., 1976; Wiley et al., 2005). However, these are 6 
not yet well characterised. As such considerable further work is required to assess the 7 
effects of both purified single pCBs as well as combinations of numerous pCBs. With 8 
the recent UK approval of the ∆9THC CBD combination in Sativex, it can be clearly 9 
seen that the use of pCBs in the clinic is gaining public acceptance that regulatory 10 
bodies are willing to accept plant-derived medicines alongside their synthetic 11 
counterparts. Indeed, non-∆9THC pCBs may represent an untapped clinical potential for 12 
a number of feeding disorders. Such a need is particularly important given the non-13 
specific behavioural side effects associated with the use of ∆9THC and its analogues in 14 
the clinic. Given the encouraging results demonstrating non-∆9THC pCB-mediated 15 
modulation of feeding, it is tempting to suggest that these compounds may provide at 16 
least the basis for novel therapies for the treatment of feeding disorders. 17 
 18 
 19 
 20 
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Figure 1; the development of cannabinoid pharmacology 1964 – 2010.  1 
Figure 2; eCB signalling pathways. Upon invasion of an action potential into the 2 
synaptic region of the presynapse, the release of neurotransmitter (in this case glutamate 3 
or acetylcholine) and the binding of neurotransmitter to postsynaptic receptor sites: the 4 
eCBs AEA and 2-AG are produced on demand from arachidonic acid by NaPE and 5 
DAG respectively and released into the synaptic cleft from the postsynapse (red). Upon 6 
neurotransmitter binding to both metabotropic Glutamate and Acetylcholine receptors G 7 
subunits disassociate and stimulate an increase in PLC-β levels. This leads to an 8 
upregulation of intracellular IP3 which gates calcium channels on the endoplasmic 9 
reticulum thus increasing intracellular Ca
2+
. Furthermore, the release of Gαi/o subunits 10 
upregulates the production of cAMP and therefore allows further Ca
2+
 entry into the cell 11 
via VGCCs. Equally upon activation of iGluR channels calcium is allowed into the cell. 12 
Once released into the extracellular space the endocannabinoids bind to CB1R sites on 13 
the presynapse (green) causing the presynaptic cell to move closer to its resting 14 
membrane potential principally by closing VGCCs and opening VGPCs thus reducing 15 
the available intracellular Ca
2+
 required to facilitate further neurotransmitter release. 16 
Figure 3; simplified diagram illustrating retrograde signalling by eCBs in the CNS. 17 
Following vesicular neurotransmitter release from the presynaptic cell (green), 18 
neurotransmitters bind to receptor proteins (black) on the postsynaptic cell (red) 19 
stimulating eCB production and release from the postsynaptic cell. eCBs then diffuse 20 
back across the synaptic cleft and bind to CBRs (blue) on the presynaptic cell. This 21 
predominately leads to a suppression of [Ca
+
] influx but also an increase in [K
+
] efflux, 22 
thus hyperpolarising the presynaptic cell and inhibiting further neurotransmitter release.  23 
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Table 1; endocannabinergic tone effecter ligands. A brief overview of the CBR ligands 1 
discussed throughout this review, giving further background to their discovery and 2 
where appropriate their non-feeding effects.  3 
Abbreviations: 2-AG, 2-archidonlyglycerol; ∆8THC, ∆8tetrahydrocannabinol; ∆9THC, 4 
∆9tetrahydrocannabinol; ∆9THCA, ∆9tetrahydrocannbinolic acid; ∆9THCV, 5 
∆9tetrahydrocannbivarin; AEA, anandamide; CB1R, cannabinoid type 1 receptor; CB2R, 6 
cannabinoid type 2 receptor; CBR, cannabinoid receptor; CNS, central nervous system; 7 
FAAH, fatty acid amide hydrolase; MAGL, monoacylglycerol lipase; OEA, n-8 
oleoylethanolamide; P-gp, p-glycoprotein; VR1, transient receptor potential vanniliod 1; 9 
TRPA1, transient receptor potential cation channel, subfamily A, member 1. 10 
 11 
